• undefined
      • undefined
    1. Home
    2. People
    3. Vanderlaan, Albert

    Albert Vanderlaan

    Partner

    Boston

    Albert Vanderlaan leads Orrick’s Capital Markets practice. He counsels public and private companies, investment banks, venture capital firms, SPACs and SPAC sponsors focused on the high-growth technology and life sciences sectors. Albert advises these clients on a variety matters, including securities offerings, securities law compliance and corporate governance matters.

    Albert is involved in a broad range of corporate legal engagements for high growth technology companies, including IPOs, follow-on public offerings, private and public company securities law compliance matters, public company disclosure obligations, venture financings, mergers and acquisitions, de-SPAC transactions and SPAC IPOs. He also regularly advises public and private companies and their boards of directors on corporate governance issues.

    Albert's clients include public and private companies in technology, energy, automotive, Internet related industries, real estate, finance and the life sciences (including, among others, immuno-oncology, gene therapy, restorative cell therapy and medical device companies). He also represents underwriters in initial public offerings, follow-on offerings and PIPE offerings and venture capital firms in a variety of investment transactions.

    Albert was named to the Deal’s Top Rising Stars 2021 list, which recognizes top new partners at U.S. law firms who are “doing spectacular work in the field of deal-making and who have continued to progress in their career despite the obstacles put in front of them.”

    • Prior to joining Orrick, Albert was an attorney with Gunderson Dettmer and Cooley.

    • Albert's engagements include:

      • TD Cowen and Stifel as joint book-running managers for the $125 million follow-on offering of Ichor Holdings, Ltd.
      • Serve Robotics in several equity offerings, totaling $255 million
      • Carlyle and SK Capital in its take-private acquisition of bluebird bio
      • Kineta in its reverse merger with Yumanity Therapeutics, along with a $7.5 million PIPE financing; multiple equity offerings, totaling $26.5 million; and its pending acquisition by TuHURA
      • GKCC in its series of financings of Elicio Therapeutics, totaling more than $30 million, and its $5.8 million private placement financing of MiNK Therapeutics
      • Squadra Ventures in numerous Series Seed investments in Tidal Cyber, Falcomm, Prewitt Ridge, Net Rise, Datalogz and Primordial Labs
      • Fisker in its $2.9 billion business combination with Spartan Energy Acquisition Corp., a SPAC sponsored by an affiliate of Apollo Global Management, Inc., and a series of debt and equity offerings, totaling over $1.4 billion
      • CIIG Capital Partners II, a SPAC, in its $573 million merger with Zapp Electric Vehicles
      • Local Bounti in its $1.1 billion business combination with Leo Holdings III Corp, a SPAC sponsored by Lion Capital; as corporate and disclosure counsel in its $122.5 million acquisition of Pete's; its $23.3 million PIPE offering; and its loan refinancing with Cargill and sale leaseback transaction
      • COVA Acquisition Corp., a SPAC sponsored by Crescent Cove Advisors and affiliates targeting companies in Southeast Asia, in its upsized $300 million initial public offering and its subsequent $3.8 billion business combination with ECARX Holdings, Inc.
      • Volta in its $1.4 billion business combination with Tortoise Acquisition Corp. II, a SPAC, and its $150 million at-the-market offering
      • Dave Inc. in its $4.0 billion business combination with VPC Impact Acquisition Holdings III, Inc., a SPAC sponsored by Victory Park Capital, and its $100 million convertible note financing
      • Genesis Growth Tech Acquisition Corp., a SPAC targeting companies in Europe, in its upsized $220 million initial public offering
      • Reprise in its $62 million Series B financing
      • Locus in its $50 million Series C financing
      • Luminar Technologies in its $3.4 billion business combination with Gores Metropoulos, Inc., a SPAC sponsored by affiliates of The Gores Group, LLC and Metropoulos & Co.
      • ARMO BioSciences in its acquisition by an American Pharmaceutical Company for $1.6 billion*
      • Vanda Pharmaceuticals in its $101 million follow-on public offering*
      • Synchronoss Technologies in its sale of Intralinks Holdings, Inc. for $977 million; its acquisition of Intralinks Holdings, Inc. for $821 million; and its $230 million offering of 0.75% senior convertible notes*
      • REGENXBIO in its $250 million IPO*
      • Vitae Pharmaceuticals in its acquisition by Allergan for $639 million*

      *Please note: Albert's experience includes that prior to joining Orrick.